PURPOSE OF REVIEW: Primary HIV-1 infection is usually initiated by viruses with an exclusive affinity for the C-C chemokine receptor type 5 (CCR5) coreceptor. Viral variants that are also able to bind the C-X-C chemokine receptor type 4 (CXCR4) coreceptor arise during the course of the disease in about 50% of the infected individuals and their emergence is associated with a faster disease progression. In this article we provide a historical overview of the events that led to the discovery of the relationship between viral phenotype, coreceptor tropism and pathogenesis. RECENT FINDINGS: The prevalence of CCR5 and CXCR4-using viruses differs from study to study, but overall percentages of CXCR4 use fluctuate between 2.0 and 63.0%. The association between coreceptor use and disease stage is recognized, with the lowest X4 prevalence in seroconverters and the highest in the final stage of the disease. Up to date there are insufficient arguments to support an impact of coreceptor tropism on response to combined antiretroviral therapy (cART) or an impact of cART on coreceptor tropism evolution. SUMMARY: This review provides an overview of available data on coreceptor use in the different stages of the HIV-1 infection process. Although it is clear that CXCR4-using viruses emerge during the course of infection, the driving forces and mechanisms behind coreceptor switch remain largely unknown.
PURPOSE OF REVIEW: Primary HIV-1 infection is usually initiated by viruses with an exclusive affinity for the C-C chemokine receptor type 5 (CCR5) coreceptor. Viral variants that are also able to bind the C-X-C chemokine receptor type 4 (CXCR4) coreceptor arise during the course of the disease in about 50% of the infected individuals and their emergence is associated with a faster disease progression. In this article we provide a historical overview of the events that led to the discovery of the relationship between viral phenotype, coreceptor tropism and pathogenesis. RECENT FINDINGS: The prevalence of CCR5 and CXCR4-using viruses differs from study to study, but overall percentages of CXCR4 use fluctuate between 2.0 and 63.0%. The association between coreceptor use and disease stage is recognized, with the lowest X4 prevalence in seroconverters and the highest in the final stage of the disease. Up to date there are insufficient arguments to support an impact of coreceptor tropism on response to combined antiretroviral therapy (cART) or an impact of cART on coreceptor tropism evolution. SUMMARY: This review provides an overview of available data on coreceptor use in the different stages of the HIV-1 infection process. Although it is clear that CXCR4-using viruses emerge during the course of infection, the driving forces and mechanisms behind coreceptor switch remain largely unknown.
Authors: Guinevere Q Lee; Chris Lachowski; Eric Cai; Viviane D Lima; Yap Boum; Conrad Muzoora; Adrienne Rain Mocello; Peter W Hunt; Jeffrey N Martin; David R Bangsberg; P Richard Harrigan Journal: AIDS Date: 2016-07-17 Impact factor: 4.177
Authors: Iris Chen; Wei Huang; Matthew B Connor; Arne Frantzell; Vanessa Cummings; Geetha G Beauchamp; Sam Griffith; Sheldon D Fields; Hyman M Scott; Steven Shoptaw; Carlos Del Rio; Manya Magnus; Sharon Mannheimer; Hong-Van Tieu; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: HIV Clin Trials Date: 2016-06-14
Authors: S Baroncelli; C M Galluzzo; M Andreotti; M F Pirillo; V Fragola; L E Weimer; M Giuliano; S Vella; L Palmisano Journal: Eur J Clin Microbiol Infect Dis Date: 2013-07-04 Impact factor: 3.267
Authors: Jan Weber; Ana C Vazquez; Dane Winner; Richard M Gibson; Ariel M Rhea; Justine D Rose; Doug Wylie; Kenneth Henry; Alison Wright; Kevin King; John Archer; Eva Poveda; Vicente Soriano; David L Robertson; Paul D Olivo; Eric J Arts; Miguel E Quiñones-Mateu Journal: J Clin Microbiol Date: 2013-03-13 Impact factor: 5.948
Authors: Sieberth Nascimento-Brito; Jean Paulo Zukurov; Juliana T Maricato; Angela C Volpini; Anna Christina M Salim; Flávio M G Araújo; Roney S Coimbra; Guilherme C Oliveira; Fernando Antoneli; Luiz Mário R Janini Journal: PLoS One Date: 2015-09-28 Impact factor: 3.240